Genentech Bets on Bicycle-Based Therapies

Genentech Bets on Bicycle-Based Therapies

Genentech, a subsidiary of the Roche Group (OTCMKTS: RHHBY), is betting big on a collaboration effort with Bicycle Therapeutics plc (NASDAQ: BCYC). The exclusive collaboration agreement between the two biotechnology companies hopes to develop and commercialize Bicycle-based immuno-oncology therapies against multiple targets. Genetech will pay $30 million upfront to Bicycle Therapeutics with a potential $1.7 billion in milestone payments. You might have guessed this based on the name, but Bicycles are Bicycle Therapeutics’ trademark platform. They are fully synthetic short peptides constrained with small-molecule scaffolds to form two loops that stabilize their structural geometry.... Read More »